1.1 Venetoclax with rituximab is not recommended, within its anticipated marketing authorisation, for treating relapsed or refractory chronic lymphocytic leukaemia in adults.
Cancer 52 announced the publication of our new briefing document 'Getting a better deal for people with rare and less common cancers: the next ten years'
During our consultation process over the summer regarding what's needed for people with rare and less common cancers in the NHS ten year plan we generated views and input from more than 50 of our member charities, more than 650 patients and 14 key stakeholders.
This trial is comparing ibrutinib alongside rituximab with fludarabine, cyclophosphamide, rituximab and venetoclax for chronic lymphocytic leukaemia. This trial is for people who haven’t yet had treatment for their chronic lymphocytic leukaemia (CLL). The CLLSA supports this research.
The Flair Trial researchers think that ibrutinib with rituximab, or venetoclax, might work well for people with CLL who haven’t yet had treatment. To find this out they want to compare:
fludarabine, cyclophosphamide and rituximab (FCR)
People across the UK living with the most common form of adult leukaemia are celebrating today following NHS England's decision to remove the arbitrary clause on funding the treatment Ibrutinib following months of campaigning by the blood cancer community.
The meeting summary together with the videos and slides of the main presentations by Prof Chris Fegan and Dr Stephen Man are now available here
Prof Chris Fegan talked to “CLL treatment – who needs treatment and how do we move from where we are to cure?”
Dr Stephen Man talked about his research into T cells
The photo shows Olga Janssen Prof Chris Fegan and Dr Stephen Man on the roof of the venue 'We the curious' in Bristol.
The CLLSA has sent in a submission to NHS England (NHSE) in colaboration with Leukaemia Care.
The letter is attached below.
Living with a long-term incurable blood cancer presents many people with enormous physical and emotional pressures. We are grateful to Professor Tanya Byron for highlighting these issues in The Times.